Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma

Suguru Shirotake, Kimiharu Takamatsu, Ryuichi Mizuno, Go Kaneko, Koshiro Nishimoto, Mototsugu Oya, Masafumi Oyama

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Serum lactate dehydrogenase before nivolumab treatment could be a therapeutic prognostic biomarker for patients with metastatic clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences